FMP
EURONEXT
3.34 EUR
0.02 (0.599%)
Mr. M. Pascal Prigent
Healthcare
Biotechnology
https://www.genfit.com
EURONEXT
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic ...
N/A
FR0004163111
F43738107
Parc EurasantE
33 3 20 16 40 00
FR
154
Dec 19, 2006
-
EURONEXT
Biotechnology
Healthcare
F43738107
FR0004163111
FR
3.34
0.86
182.91k
166.04M
-
2.84-4.92
0
-
-
-
-
-4.64
-
https://www.genfit.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.